Inhibition of all-TRANS-retinoic acid metabolism by R116010 induces antitumour activity

[1]  W. Miller.  The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer , 1998, Cancer.

[2]  B. van der Burg,et al.  Human retinoic acid (RA) 4-hydroxylase (CYP26) is highly specific for all-trans-RA and can be induced through RA receptors in human breast and colon carcinoma cells. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[3]  L. Dillen,et al.  The antiproliferative activity of all-trans-retinoic acid catabolites and isomers is differentially modulated by liarozole-fumarate in MCF-7 human breast cancer cells. , 1998, British Journal of Cancer.

[4]  F. Dilworth,et al.  cDNA Cloning of Human Retinoic Acid-metabolizing Enzyme (hP450RAI) Identifies a Novel Family of Cytochromes P450 (CYP26)* , 1997, The Journal of Biological Chemistry.

[5]  B. van der Burg,et al.  Autoinduction of Retinoic Acid Metabolism to Polar Derivatives with Decreased Biological Activity in Retinoic Acid-sensitive, but Not in Retinoic Acid-resistant Human Breast Cancer Cells* , 1997, The Journal of Biological Chemistry.

[6]  F. Ramaekers,et al.  Liarozole potentiates the all-trans-retinoic acid-induced structural remodelling in human breast carcinoma MCF-7 cells in vitro. , 1996, European journal of cell biology.

[7]  J. H. Choi,et al.  Highly specific cytochrome P450-like enzymes for all-trans-retinoic acid in T47D human breast cancer cells. , 1996, The Journal of clinical endocrinology and metabolism.

[8]  D. End,et al.  A rapid assay for measuring the metabolism of [3H]-retinoic acid in cell cultures. , 1995, Journal of pharmacological and toxicological methods.

[9]  M. Moeremans,et al.  Liarozole, an antitumor drug, modulates cytokeratin expression in the dunning AT‐6sq prostatic carcinoma through in situ accumulation of all‐trans‐retinoic acid , 1995, The Prostate.

[10]  H. Scher,et al.  Differences in the pharmacokinetic properties of orally administered all-trans-retinoic acid and 9-cis-retinoic acid in the plasma of nude mice. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[11]  R. Warrell,et al.  Elevated plasma lipid peroxide content correlates with rapid plasma clearance of all-trans-retinoic acid in patients with advanced cancer. , 1994, Cancer research.

[12]  M. Coene,et al.  Liarozole fumarate inhibits the metabolism of 4-keto-all-trans-retinoic acid. , 1994, Biochemical pharmacology.

[13]  S. Lippman,et al.  Phase I evaluation of all-trans-retinoic acid in adults with solid tumors. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  H. Bossche.  Inhibitors of P450-dependent steroid biosynthesis: From research to medical treatment , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[15]  J. van Dun,et al.  Effects of liarozole, a new antitumoral compound, on retinoic acid-induced inhibition of cell growth and on retinoic acid metabolism in MCF-7 human breast cancer cells. , 1992, Cancer research.

[16]  E. Dmitrovsky,et al.  Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. , 1992, Blood.

[17]  P. Janssen,et al.  R 76713 and enantiomers: selective, nonsteroidal inhibitors of the cytochrome P450-dependent oestrogen synthesis. , 1990, Biochemical pharmacology.

[18]  M. Kris,et al.  Modulation of all-trans retinoic acid pharmacokinetics by liarozole , 2004, Cancer Chemotherapy and Pharmacology.

[19]  L. Dillen,et al.  Induction of the oxidative catabolism of retinoid acid in MCF-7 cells. , 1997, British Journal of Cancer.

[20]  J. Schalken,et al.  Antitumoral effects of liarozole in androgen-dependent and independent R3327-Dunning prostate adenocarcinomas. , 1994, The Journal of urology.

[21]  H. Kornhuber,et al.  Oral Liarozole as a Catabolic Inhibitor Potently Increases Retinoic Acid in vivo: First Experience from an Ongoing Therapeutic Trial in Highly Malignant Primary Brain Tumors , 1993 .

[22]  P. Janssen,et al.  R 75251, a new inhibitor of steroid biosynthesis , 1990, The Prostate.

[23]  P. Janssen,et al.  Antitumoral effects of R 75251 on the growth of transplantable R3327 prostatic adenocarcinoma in rats , 1990, The Prostate.